Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence

References

• Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777–79. doi:10.1097/INF.0000000000000282.
   PubMed Web of Science ®Google Scholar
• Baccarini C, Ternouth A, Wieffer H, Vyse A. The changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother. 2013;9(1):162–71. doi:10.4161/hv.22302.
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397–403. doi:10.1016/S0140-6736(06)67932-4.
   PubMed Web of Science ®Google Scholar
• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3–B9. doi:10.1016/j.vaccine.2011.12.062.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51–63. doi:10.1016/j.vaccine.2009.04.063.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2016. [accessed 2018 Apr 2]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report.pdf.
   Google Scholar
• European Centre for Disease Prevention and Control. Invasive meningococcal disease. [accessed 2017 Nov 11]. https://ecdc.europa.eu/sites/portal/files/documents/Invasive%20meningococcal%20disease%20AER.pdf.
   Google Scholar
• Wong CA, Taylor JA, Wright JA, Opel DJ, Katzenellenbogen RA. Missed opportunities for adolescent vaccination, 2006-2011. J Adolesc Health. 2013;53(4):492–97. doi:10.1016/j.jadohealth.2013.05.009.
   PubMed Web of Science ®Google Scholar
• Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, Williams CL, Meyer SA, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(33):874–82. doi:10.15585/mmwr.mm6633a2.
   PubMed Web of Science ®Google Scholar
• Adams SH, Park MJ, Twietmeyer L, Brindis CD, Irwin CE Jr. Association between adolescent preventive care and the role of the Affordable Care Act. JAMA Pediatr. 2017;172(1):43–48. doi:10.1001/jamapediatrics.2017.3140.
   Web of Science ®Google Scholar
• National Center for Immunization and Respiratory Diseases. General recommendations on immunization–recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(2):1–64.
   Google Scholar
• Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620–24.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for diphtheria. [accessed 2017 Nov 9]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for human papillomavirus infection. [accessed 2017 November 9]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for tetanus. [accessed 2017 November 9]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for pertussis. [accessed 2017 November 9]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for influenza. [accessed 2017 November 9]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for meningococcal disease. [accessed 2017 July 20]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years, United States, 2017. [accessed 2017 July 18]. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedule for adults aged 19 years or older, United States, 2017. [accessed 2017 June 21]. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for hepatitis B. [accessed 2019 March 6]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• European Centre for Disease Prevention and Control. Recommended immunisations for varicella. [accessed 2019 March 6]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx.
   Google Scholar
• Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28(34):5513–23. doi:10.1016/j.vaccine.2010.06.026.
   PubMed Web of Science ®Google Scholar
• Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gomez-Campdera JA, Navarro ML, Merino JM, Martin-Ancel A, Roca J, Garcia-Del-Ri M, et al. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine coadministered with a Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr Infect Dis J. 2007;26(1):1–7. doi:10.1097/01.inf.0000247070.60063.09.
   PubMed Web of Science ®Google Scholar
• Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C, Poolman J, Boutriau D. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25(51):8487–99. doi:10.1016/j.vaccine.2007.10.013.
   PubMed Web of Science ®Google Scholar
• Kitchin NR, Southern J, Morris R, Hemme F, Thomas S, Watson MW, Cartwright K, Miller E. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child. 2007;92(1):11–16. doi:10.1136/adc.2005.076109.
   PubMed Web of Science ®Google Scholar
• Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine. 2006;24(2):215–19. doi:10.1016/j.vaccine.2005.07.060.
   PubMed Web of Science ®Google Scholar
• Menactra® (MCV4). Full Prescribing Information. Swiftwater (PA): Sanofi Pasteur Inc.; 2014.
   Google Scholar
• Menveo® (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full Prescribing Information. Sovicille (Italy): Novartis; 2013.
   Google Scholar
• Pfizer Canada Inc. Nimenrix Product Monograph. Kirkland (QC, Canada): Pfizer Canada Inc; 2016.
   Google Scholar
• MenAfriVac (meningococcal A conjugate vaccine). Full Prescribing Information. Pune (India): Serum Institute of India; 2015.
   Google Scholar
• Menjugate 10 micrograms suspension for injection (meningococcal group C conjugate vaccine). Summary of Product Characteristics. Sovicille (Italy): Novartis Vaccines and Diagnostics S.r.l.; 2016.
   Google Scholar
• Meningitec (meningococcal serogroup c conjugate vaccine). Full Prescribing Information. West Ryde (NSW, Australia): Pfizer Australia Pty Ltd; 2011.
   Google Scholar
• NeisVac-C (meningococcal C conjugate vaccine). Full Prescribing Information. New York (NY): Pfizer; 2015.
   Google Scholar
• MENHIBRIX® (Hib-MenCY-TT). Full Prescribing Information. Rixensart (Belgium): GlaxoSmithKline; 2013.
   Google Scholar
• Menitorix (Haemophilus type b and meningococcal group C conjugate vaccine). Summary of Product Characteristics. Middlesex (UK): SmithKline Beecham PLC; 2015.
   Google Scholar
• Ministerio de Salud (Gobierno de Chile). Vaccination Calendar 2017. [accessed 2017 August 29]. http://vacunas.minsal.cl/calendario-de-vacunacion-2017/.
   Google Scholar
• State of Kuwait. Schedule of essential vaccination by age, State of Kuwait, 2008. [accessed 2017 August 29]. https://www.e.gov.kw/sites/kgoEnglish/Pages/CitizensResidents/Health/BasicVaccinationsInKuwait.aspx.
   Google Scholar
• Kingdom of Saudia Arabia Ministry of Health. Vaccination certificate. [accessed 2017 August 29]. http://www.moh.gov.sa/HealthAwareness/EducationalContent/HealthInstructions/Documents/جدول%20التطعيمات.pdf.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–2):1–28.
   PubMed Web of Science ®Google Scholar
• Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013;31(41):4477–86. doi:10.1016/j.vaccine.2013.07.083.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2):e20162193. doi:10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar
• Trumenba®. Meningococcal group B vaccine. Philadelphia (PA): Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc; 2016.
   Google Scholar
• Bexsero® (Meningococcal group B vaccine). Full Prescribing Information. Cambridge (MA, USA): Novartis Vaccines and Diagnostics, Inc; 2015.
   Google Scholar
• National Advisory Committee on Immunization. Advice for the use of the multicomponent meningococcal serogroup B (4CMenB) vaccine. [accessed 2017 August 29]. http://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-104-2014-eng.pdf.
   Google Scholar
• Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease C. Control and Prevention (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):608–12.
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171–76. doi:10.15585/mmwr.mm6441a3.
   PubMed Web of Science ®Google Scholar
• Patton ME, Stephens D, Moore K, MacNeil JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509–13. doi:10.15585/mmwr.mm6619a6.
   PubMed Web of Science ®Google Scholar
• Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, Martin S, Thornton C, Goldblatt D, Corbel M, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun. 2002;70(9):4946–54.
   PubMed Web of Science ®Google Scholar
• Southern J, Gelb D, Andrews N, Waight PA, Morris R, Cartwright K, Miller E. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Hum Vaccin. 2006;2:237–42.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Sy LS, Ackerson BK, Hechter RC, Tartof SY, Haag M, Slezak JM, Luo Y, Fischetti CA, Takhar HS, et al. Safety of quadrivalent meningococcal conjugate vaccine in 11- to 21-year-olds. Pediatrics. 2017;139:1. doi:10.1542/peds.2016-2084.
   Web of Science ®Google Scholar
• Broderick MP, Romero-Steiner S, Rajam G, Johnson SE, Milton A, Kim E, Choi LJ, Radin JM, Schmidt DS, Carlone GM, et al. Immune responses in U.S. military personnel who received meningococcal conjugate vaccine (MenACWY) concomitantly with other vaccines were higher than in personnel who received MenACWY alone. Clin Vaccine Immunol. 2016;23(8):672–80. doi:10.1128/cvi.00267-16.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Expert Committee on biological standardization: Twenty-seventh report. [accessed 2018 August 3]. http://apps.who.int/iris/bitstream/handle/10665/37954/WHO_TRS_594.pdf?sequence=1&isAllowed=y.
   Google Scholar
• Keiser P, Gill C. Defining efficacy in meningococcal vaccine trials. Future Sci. 2012;2:589–601.
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection—serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–27. doi:10.1016/j.vaccine.2005.01.051.
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–86. doi:10.1128/CDLI.10.5.780-786.2003.
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–26.
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, Findlow J, Hoiby EA, Rosenqvist E, Balmer P, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12(8):970–76. doi:10.1128/CDLI.12.8.970-976.2005.
   PubMedGoogle Scholar
• McIntosh ED, Broker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays - the role of complement in infection and immunity. Vaccine. 2015;33(36):4414–21. doi:10.1016/j.vaccine.2015.07.019.
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112–116. doi:10.1016/j.vaccine.2009.04.065.
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, et al. Neisseria meningitidis group B correlates of protection and assay standardization–international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24(24):5093–107.
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28(18):3171–79. doi:10.1016/j.vaccine.2010.02.045.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, Ceddia F. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol. 2010;17(4):537–44. doi:10.1128/cvi.00436-09.
   PubMed Web of Science ®Google Scholar
• Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673–82. doi:10.1097/INF.0000000000001124.
   PubMed Web of Science ®Google Scholar
• Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden J, Jones TR, York LJ, Jansen KU, O’Neill RE, Harris SL, et al. Immunogenicity, tolerability, and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548–54. doi:10.1097/INF.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O’Neill RE, York LJ, et al. Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents. J Pediatric Infect Dis Soc. 2016;5(2):180–87. doi:10.1093/jpids/piv064.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM, Marshall GS, Catteau G, Dobbelaere K, Descamps D, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30(12):e225–234. doi:10.1097/INF.0b013e31822d28df.
   PubMed Web of Science ®Google Scholar
• Product Monograph: Menactra®. [accessed 2018 June 5]. https://www.vaccineshoppecanada.com/document.cfm?file=menactra_e.pdf.
   Google Scholar
• Gasparini R, Johnston W, Conversano M, Garscadden A, Alexanderian D, Giglioli N, Percell S, Han L, Smolenov I. Immunogenicity and safety of combined tetanus, reduced diphtheria, acellular pertussis vaccine when co-administered with quadrivalent meningococcal conjugate and human papillomavirus vaccines in healthy adolescents. J Vaccines Vaccin. 2014;5:231. doi:10.4172/2157-7560.1000231.
   Google Scholar
• Ostergaard L, Silfverdal SA, Berglund J, Flodmark CE, West C, Bianco V, Baine Y, Miller JM. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11-17 years: an open, randomised, controlled trial. Vaccine. 2012;30(4):774–83. doi:10.1016/j.vaccine.2011.11.051.
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, Sings HL, Haupt RM, Garner EI, Protocol 025 Investigators. Safety, tolerability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics. 2010;125(6):1142–51. doi:10.1542/peds.2009-2336.
   PubMed Web of Science ®Google Scholar
• Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, Engel E, Huicho L, Shew M, Maansson R, et al. Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines. Pediatrics. 2015;136(3):e563–572. doi:10.1542/peds.2014-4199.
   PubMed Web of Science ®Google Scholar
• Clinical review of Biologics License Application for human papillomavirus 6, 11, 16, 18 L1 virus like particle vaccine (S. cerevisiae) (STN 125126 GARDASIL), manufactured by Merck, Inc. [accessed 2018 May 9]. http://wayback.archive-it.org/7993/20170723091811/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111287.pdf.
   Google Scholar
• US Food and Drug Administration. Clinical review of biologics license application supplement STN# 125126/1297.0 – male indication for GARDASIL. [accessed 2017 October 31]. http://wayback.archive-it.org/7993/20170722072813/https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM190977.pdf.
   Google Scholar
• Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant). Full prescribing information. Whitehouse Station (NJ): Merck & Co., Inc.; 2014.
   Google Scholar
• Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Hlavata LC, Forleo-Neto E, Dagnew AF, Arora AK. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. J Travel Med. 2015;22(1):48–56. doi:10.1111/jtm.12164.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, Forleo-Neto E, Gniel D, Dagnew AF, Arora AK. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis. 2014;12(5):485–93. doi:10.1016/j.tmaid.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, Reisinger EC, Meyer S, Forleo-Neto E, Dagnew AF, Arora AK. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults. J Travel Med. 2015;22(2):105–14. doi:10.1111/jtm.12180.
   PubMed Web of Science ®Google Scholar
• Ambrosino DM, Siber GR. Simultaneous administration of vaccines for Haemophilus influenzae type b, pneumococci, and meningococci. J Infect Dis. 1986;154:893–96.
   PubMed Web of Science ®Google Scholar
• Tashani M, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Rashid H, Booy R. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial. Vaccine. 2016;34(48):5929–37. doi:10.1016/j.vaccine.2016.10.020.
   PubMed Web of Science ®Google Scholar
• Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, Dbaibo G, Bianco V, Baine Y, Miller J. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. Hum Vaccin Immunother. 2012;8(7):881–87. doi:10.4161/hv.20212.
   PubMed Web of Science ®Google Scholar
• Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–30. doi:10.1016/j.vaccine.2015.05.027.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82. doi:10.1001/jama.2012.85.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. doi:10.1016/S0140-6736(12)61961-8.
   PubMed Web of Science ®Google Scholar
• Society for Adolescent Health and Medicine. Establishing an immunization platform for 16-year-olds in the United States. J Adolesc Health. 2017;60(4):475–76. doi:10.1016/j.jadohealth.2017.01.011.
   PubMedGoogle Scholar
• Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination coverage among children aged 19-35 months - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1171–77. doi:10.15585/mmwr.mm6643a3.
   PubMed Web of Science ®Google Scholar
• Rand CM, Goldstein NPN. Patterns of primary care physician visits for US adolescents in 2014: implications for vaccination. Acad Pediatr. 2018;18(2s):S72–S78. doi:10.1016/j.acap.2018.01.002.
   PubMedGoogle Scholar
• Immunization of adolescents. Recommendations of the Advisory Committee on Immunization practices, the American academy of pediatrics, the American academy of family physicians, and the American Medical Association. MMWR Recomm Rep. 1996;45(RR–13):1–16.
   Google Scholar
• Robinson CL, Romero JR, Kempe A, Pellegrini C, Advisory Committee on Immunization Practices Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017;66(5):134–35. doi:10.15585/mmwr.mm6605e1.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR–7):1–21.
   PubMedGoogle Scholar
• Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377:2349–62. doi:10.1056/NEJMoa1614474.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Block SL, Szenborn L, Daly W, Jackowska T, D’Agostino D, Han L, Dull PM, Smolenov I. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–10. doi:10.1016/j.vaccine.2015.03.001.
   PubMed Web of Science ®Google Scholar